Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9ULK5
UPID:
VANG2_HUMAN
Alternative names:
Loop-tail protein 1 homolog; Strabismus 1; Van Gogh-like protein 2
Alternative UPACC:
Q9ULK5; D3DVE9; Q5T212
Background:
Vang-like protein 2, also known as Loop-tail protein 1 homolog, Strabismus 1, and Van Gogh-like protein 2, plays a pivotal role in early morphogenesis and patterning of axial midline structures and neural plate development. It is crucial for the regulation of planar cell polarity, especially in the orientation of stereociliary bundles in the cochlea, and is involved in myocardializing cells' polarization and movement in the outflow tract through RHOA signaling.
Therapeutic significance:
Given its involvement in neural tube defects, a condition stemming from defective neural tube closure linked to both genetic and environmental factors, Vang-like protein 2 represents a significant target for therapeutic intervention. Understanding the role of Vang-like protein 2 could open doors to potential therapeutic strategies.